Patents by Inventor Peter S. Linsley

Peter S. Linsley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10370428
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: August 6, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Robert James Peach, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
  • Publication number: 20190185538
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 20, 2019
    Inventors: Robert James Peach, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
  • Publication number: 20180305768
    Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.
    Type: Application
    Filed: March 1, 2018
    Publication date: October 25, 2018
    Applicants: The Netherlands Cancer Institute, Merck Sharp & Dohme Corp.
    Inventors: HongYue Dai, Yudong He, Peter S. Linsley, Mao Mao, Christopher J. Roberts, Laura Johanna Van't Veer, Marc J. Van de Vijver, Rene Bernards, A.A. M. Hart
  • Publication number: 20180134764
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Application
    Filed: August 4, 2017
    Publication date: May 17, 2018
    Inventors: Robert James PEACH, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
  • Patent number: 9909185
    Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: March 6, 2018
    Assignees: THE NETHERLANDS CANCER INSTITUTE, MERCK SHARP & DOHME CORP.
    Inventors: HongYue Dai, Yudong He, Peter S. Linsley, Mao Mao, Christopher J. Roberts, Laura Johanna Van't Veer, Marc J. Van de Vijver, Rene Bernards, A.A. M. Hart
  • Publication number: 20170369549
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Application
    Filed: August 4, 2017
    Publication date: December 28, 2017
    Inventors: Robert James PEACH, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
  • Patent number: 9758565
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: September 12, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert James Peach, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
  • Patent number: 9200275
    Abstract: In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one at least one small interfering RNA agent (iRNA), wherein said iRNA comprises a nucleotide sequence of at least 15 nucleotides, wherein the nucleotide sequence comprises a seed region consisting of nucleotide positions 1 to 12, wherein position 1 represents the 5? end of the iRNA nucleotide sequence and wherein said seed region comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to six contiguous nucleotides within positions 1 to 12 of a nucleotide sequence, wherein position 1 represents the 5?end of the nucleotide sequence, wherein the nucleotide sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: December 1, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter S. Linsley, Janell Schelter, Julja Burchard, Lee Lim, Miho Kibukawa
  • Publication number: 20150071914
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Application
    Filed: May 29, 2014
    Publication date: March 12, 2015
    Applicant: Bristol-Myers Squibb Company
    Inventors: Robert James PEACH, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
  • Patent number: 8785398
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: July 22, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert James Peach, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
  • Patent number: 8609830
    Abstract: The invention provides methods and compositions for gene silencing by RNA interference. In particular, the invention provides methods for gene silencing or RNA knockdown using small interfering RNAs (siRNAs) having partial sequence homology to its target gene. The invention also provides methods for identifying common and/or differential responses to a plurality of different siRNAs targeting a gene. The invention also provides methods for evaluating the relative activity of the two strands of an siRNA. The invention further provides methods of designing siRNAs for gene silencing. The invention further provides methods of using siRNAs as therapeutics for treatment of diseases.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: December 17, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Aimee L. Jackson, Steven R. Bartz, Julja Burchard, Janell M. Schelter, Peter S. Linsley
  • Patent number: 8457902
    Abstract: The present invention provides a method for identifying siRNA target motifs in a transcript using a position-specific score matrix approach. The invention also provides a method for identifying off-target genes of an siRNA using a position-specific score matrix approach. The invention further provides a method for designing siRNAs with higher silencing efficacy and specificity. The invention also provides a library of siRNAs comprising siRNAs with high silencing efficacy and specificity.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: June 4, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Aimee L. Jackson, Steven R. Bartz, Julja Burchard, Peter S. Linsley, Ge Wei, Guy L. Cavet
  • Patent number: 8399248
    Abstract: In one aspect, the invention generally relates to use of miR-34 as a biomarker to estimate TP53 function in a cell. In another aspect, the invention generally relates to multiple uses of miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: March 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michele A. Cleary, Aimee L. Jackson, Peter S. Linsley, Julja Burchard, Lee P. Lim, Jill F. Magnus, Lin He, Xingyue He, Scott W. Lowe, Gregory J. Hannon
  • Patent number: 8378088
    Abstract: In one aspect, the invention generally relates to compositions comprising miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: February 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michele A Cleary, Aimee L Jackson, Peter S Linsley, Julja Burchard, Lee P Lim, Jill F Magnus
  • Publication number: 20120072124
    Abstract: The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.
    Type: Application
    Filed: August 10, 2011
    Publication date: March 22, 2012
    Inventors: Jerald P. Radich, Hongyue Dai, Mao Mao, Janell M. Schelter, Peter S. Linsley
  • Publication number: 20120052065
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Application
    Filed: October 20, 2011
    Publication date: March 1, 2012
    Inventors: Robert J. Peach, Joseph R. Naemura, Peter S. Linsley, Jurgen Bajorath
  • Publication number: 20110301048
    Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.
    Type: Application
    Filed: November 23, 2010
    Publication date: December 8, 2011
    Applicants: MERCK SHARP & DOHME CORP., THE NETHERLANDS CANCER INSTITUTE
    Inventors: HongYue Dai, Yudong He, Peter S. Linsley, Mao Mao, Christopher J. Roberts, Laura Johanna Van't Veer, Marc J. Van de Vijver, Rene Bernards, A.A. M. Hart
  • Publication number: 20110250591
    Abstract: The present invention provides a method for identifying siRNA target motifs in a transcript using a position-specific score matrix approach. The invention also provides a method for identifying off-target genes of an siRNA using a position-specific score matrix approach. The invention further provides a method for designing siRNAs with higher silencing efficacy and specificity. The invention also provides a library of siRNAs comprising siRNAs with high silencing efficacy and specificity.
    Type: Application
    Filed: May 4, 2011
    Publication date: October 13, 2011
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Aimee L. Jackson, Steven R. Bartz, Julja Burchard, Peter S. Linsley, Wei Ge, Guy L. Cavet
  • Patent number: 8014957
    Abstract: The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: September 6, 2011
    Assignees: Fred Hutchinson Cancer Research Center, Rosetta Inpharmatics LLC
    Inventors: Jerald P. Radich, Hongyue Dai, Mao Mao, Janell M. Schelter, Peter S. Linsley
  • Patent number: 7962316
    Abstract: The present invention provides a method for identifying siRNA target motifs in a transcript using a position-specific score matrix approach. The invention also provides a method for identifying off-target genes of an siRNA using a position-specific score matrix approach. The invention further provides a method for designing siRNAs with higher silencing efficacy and specificity. The invention also provides a library of siRNAs comprising siRNAs with high silencing efficacy and specificity.
    Type: Grant
    Filed: October 27, 2004
    Date of Patent: June 14, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Aimee L. Jackson, Steven R. Bartz, Julja Burchard, Peter S. Linsley, Wei Ge, Guy L. Cavet